We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Treatment of systemic lupus erythematosus with epratuzumab.
- Authors
Traczewski, Pawel; Rudnicka, Lidia
- Abstract
Systemic lupus erythematosus is a prototypic autoimmune disease characterized by abnormalities in the activity of B-cells and T-cells. A novel specific treatment for autoimmune diseases is B-cell depletion with monoclonal antibodies. Epratuzumab is a monoclonal antibody that targets CD22 antigen on B-cells. Initial phase II and two terminated early phase III studies suggest that treatment of systemic lupus erythematosus with this immunomodulatory agent is effective, well tolerated and significantly improves the patient's quality of life. In vitro studies and clinical trials with non-Hodgkin lymphoma patients indicate epratuzumab can potentially serve as a complementary drug in combination therapy with another inhibitor of B-cell activity, rituximab, which is a monoclonal anti-CD20 antibody.
- Publication
British journal of clinical pharmacology, 2011, Vol 71, Issue 2, p175
- ISSN
1365-2125
- Publication type
Journal Article
- DOI
10.1111/j.1365-2125.2010.03767.x